Roger Hart was a Scientific Director in the Drug Substance Technology Division within Process Development at Amgen. His responsibilities included the identification and advancement of emerging technologies for therapeutic development and manufacturing; and cross-functional sponsorship and oversight of strategic technology development initiatives. Prior to joining Amgen, Dr. Hart completed his Ph.D. research under James E. Bailey at the California Institute of Technology where he researched the isolation of recombinant proteins from inclusion bodies. He then completed postdoctoral research at Genentech in the field of protein folding and liquid extraction under Dr. Stuart Builder. He subsequently joined the scientific staff at Genentech and contributed to development of some of Genentech’s earliest mAb projects. During his 25 years working at Amgen, he advanced the development of numerous protein, peptide, and mAb products from the early therapeutic development stage through commercial licensure. His great passion involves developing technology which can be used to advance the deep and ever-changing product pipeline within the Biopharmaceutical field and is an author of numerous patents and publications in the field.
Roger A. Hart
Scientific Director (retired)